Skip to main content
FinSpry Logo
FinSpry
GLUE logo
GLUE
(NASDAQ)
Monte Rosa Therapeutics, Inc.
$17.09-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Monte Rosa Therapeutics (GLUE) Stock Price & Financial Analysis

Monte Rosa Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$16.61 - $17.88
52-Week High$25.77
52-Week Low$3.50
Open$16.61
Volume1.24M
Average Volume (3M)1.24M
Market Cap1.06B
Shares Outstanding61.79M
P/E Ratio (TTM)50.65
Price to Sales (P/S)5.84
Price to Book (P/B)4.32
EV/EBITDA53.01
Revenue (TTM)181.54M
Net Income (TTM)20.95M
Free Cash Flow (TTM)145.02M
EPS (TTM)$0.34
Profit Margin11.54%
Operating Margin4.69%
Return on Equity (ROE)8.52%
Debt to Equity0.16
50-Day MA$18.42
200-Day MA$12.16
52-Week Change287.58%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Monte Rosa Therapeutics

What is the current stock price for GLUE?

As of the latest trading session, GLUE stock trades at $17.09. The 52-week range is $3.50–$25.77, with a day range of $16.61–$17.88.

What is the P/E ratio for GLUE?

Monte Rosa Therapeutics's trailing P/E ratio is 50.6, meaning investors pay $50.6 for every $1 of annual earnings. Monte Rosa Therapeutics operates in the Healthcare sector.

Does GLUE pay dividends?

Monte Rosa Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for GLUE?

Based on 6 analysts, the consensus for GLUE is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of GLUE?

Monte Rosa Therapeutics's market capitalization is $1.06B, classifying it as a small-cap company. Monte Rosa Therapeutics operates in the Healthcare sector within the Biotechnology industry.